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As the number of effective treatment options has increased, the management of patients with hepato-
cellular carcinoma has become complex. The most appropriate therapy depends largely on the functional
status of the underlying liver. In patients with advanced cirrhosis and tumor extent within the Milan criteria,
liver transplantation is clearly the best option, as this therapy treats the cancer along with the underlying
hepatic parenchymal disease. As the results of transplantation has become established in patients with
limited disease, investigation has increasingly focused on downstaging patients with disease outside of
Milan criteria and defining the upper limits of transplantable tumors. In patients with well preserved
hepatic function, liver resection is the most appropriate and effective treatment. Hepatic resection is not
as constrained by tumor extent and location to the same degree as transplantation and ablative therapies.
Some patients who recur after resection may still be eligible for transplantation. Ablative therapies,
particularly percutaneous radiofrequency ablation and transarterial chemoembolization have been used
primarily to treat patients with low volume irresectable tumors. Whether ablation of small tumors provides
long term disease control that is comparable to resection remains unclear.
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Introduction
Hepatocellular carcinoma (HCC) is the 5th most common cancer
in the world and is the leading cause of cancer death in many
areas. In the United States, HCC incidence is rising and is pro-
jected to further increase over the next two decades.1–3 Cirrhosis
and chronic hepatitis infection are important risk factors for
developing HCC, and globally HCC incidence is closely linked to
these conditions. Hepatitis C is an important underlying factor,
particularly in the United States, where approximately 4 million
people are afflicted with chronic hepatitis C infection, one third of
which will go on to develop chronic liver disease and a large
proportion will develop cancer.4 In general, the incidences of cir-
rhosis and HCC are closely related, but there is some variability
depending on geographic location, which reflects differences in
etiology.5 Areas with high rates of hepatitis C infection tend to
have higher rates of HCC arising in the setting of cirrhosis, in
contrast to areas where hepatitis B is more prevalent.
The presence of underlying hepatic parenchymal disease is
critically important in determining both treatment options and
outcome. The extent of the underlying hepatic dysfunction often
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dictates the therapeutic options may well be more important than
cancer extent in determining survival. Patients with advanced cir-
rhosis, with or without cancer, have a very high risk of mortality
related to liver failure and the sequelae of portal hypertension,
which is as high as 55% at one year in patients in the Child-Pugh
C category.6 In such patients, aggressive treatment of the neoplas-
tic disease may well offer little survival benefit, if the underlying
liver disease is not addressed as part of the therapy (ie, transplan-
tation); resection or even ablative therapies are usually contrain-
dicated, given the risk of precipitating liver failure. On the other
hand, patients with normal livers or with well compensated cir-
rhosis are typically limited more by the extent of the malignant
disease. In this setting, resection, orthotopic liver transplantation
(OLT) or ablative therapies are potentially available, depending on
disease related factors.
Over the past several years, surveillance programs have been
used with greater frequency in high risk patients,7 resulting in
earlier detection. Also, from a treatment standpoint, OLT and
ablative techniques have emerged as potentially effective alterna-
tives to resection, which had previously been considered the gold
standard. As a result, the best treatment strategy for patients with
early stage tumors has become increasingly controversial. Defini-
tive prospective trials directly comparing these treatment modali-
ties have not been performed, largely due to the heterogeneity
in disease extent and underlying hepatic function that make it
difficult to randomly assign patients to different treatment arms.
This section summarizes the results of a recent AHPBA con-
sensus on the surgical treatment of HCC, including the use of
ablative therapy and emerging technology, in addition to resection
and OLT.
Thermal ablation and emerging technologies in
the curative therapy of HCC
Ablative therapy
Non resectional ablative therapies have emerged as effective treat-
ment options for patients with HCC. The most common of these
approaches are radiofrequency ablation (RFA) and transarterial
embolization / transarterial chemoembolization (TAE/TACE).
These techniques are aimed at affecting tumor necrosis and can be
reasonably effective for small tumors. However, both suffer from
significant limitations. The role of TACE will not be discussed in
detail in this section, as it is addressed in depth elsewhere in this
review.
RFA is used percutaneously in the large majority of cases, but is
greatly limited by tumor size and location. In a report from Mulier
et al. that included over 5,000 treated tumors, recurrence at the
treatment site was 14% when the tumor diameter was3 cm but
increased to 25% when the diameter was 3 to 5 cm and was 58%
in tumors >5 cm in size. Vascular proximity (ie, tumors close to
major vascular structures) had similarly high recurrence rates of
37%, compared to 3% for those that were not.8 Despite these
limitations however, up to 80% tumor necrosis has been reported
for tumors that are <2.5 cm in diameter.9 In 2008, Livraghi et al.,
recorded results of a prospective multicenter analysis of percuta-
neous RFA with patients with solitary HCC 2 cm. Treatment
was successful in nearly all patients, and 5-year overall survival
was 55% but increased to 68% in patients with tumors considered
operable.10 Chen et al. recently reported equivalent overall and
disease-free survival in a randomized controlled trial comparing
resection with radiofrequency ablation for tumors up to 5 cm in
size.11 The results from these and other studies have led many to
consider RFA as an effective alternative to resection in patients
with small (3 cm) HCC.
Both percutaneous RFA and TAE/TACE are used as a primary
treatment in patients with advanced, unresectable HCC. Addi-
tionally, these approaches are used frequently to treat patients
with limited HCC while on the liver transplant waiting list. While
these ‘bridging’ techniques are employed commonly, with the aim
of controlling disease in patients while awaiting a new graft, pre-
transplantation therapy has never been shown to improve overall
disease free survival after OLT.12,13 The role of bridging therapy for
patients awaiting OLT will be discussed in more detail later in this
review.
New and emerging treatment approaches
Microwave ablation is a new modality that is promising and may
prove to be more effective than RFA for treating larger tumors
and tumors in close proximity to major vascular structures.14
However, with this greater potential comes the possibility of
increased complications. The clinical experience with microwave
ablation is still immature, and definitive conclusions regarding
its role are therefore not possible. Other modalities, such as
high intensity focused ultrasound (HIFU) and electroporation15
remain experimental at this time.
Radiofrequency-based treatment with nanoparticles is an
example of an emerging technology, currently in pre-clinical
development, with potential therapeutic applications in HCC.16,17
Consensus statement
1. RFA may have long-term survival rates similar to resection or
OLT in patients with small HCC but this must be assessed in
prospective, randomized controlled clinical trials
2. RFA is not recommended for HCC >4 cm in diameter because
of high incomplete tumor. destruction rates, and the highest
probability for complete local tumor control of HCC with RFA
occurs in tumors <2 cm in diameter.
3. Given the poor overall survival for most patients with HCC,
novel treatment avenues should be aggressively explored in an
effort to improve outcomes.
Laparoscopic And open liver resection for HCC
Open liver resection
Hepatic resection has been the primary treatment for HCC in
selected patients with limited disease. Resection has several prac-
tical advantages. First, it is more widely applicable, because there
are no restrictions on tumor size, number or macrovascular inva-
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sion, which often preclude OLT and ablation, respectively. Unlike
OLT, there is also no obligatory waiting time. Liver resection and
OLT allow complete pathologic evaluation of the specimen, which
is precluded with ablative treatment. The efficacy of partial hepa-
tectomy is critically dependent on the surgeon’s ability to achieve
a complete resection and maintain a liver remnant with adequate
volume, perfusion and biliary drainage. Outcome after resection
or OLT is closely linked to disease extent and the best outcomes
are achieved in patients with solitary, small HCC confined to
the liver without major vascular invasion. Resection is preferred
in patients with HCC and non-cirrhotic liver and is applicable
for selected patients with Child-Pugh A cirrhosis. Unlike OLT,
however, it does not address the precancerous cirrhotic liver
remnant.
The perioperative risk of partial hepatectomy for HCC has been
a critical historical issue because operative mortality rates often
exceeded 10%. Cirrhosis and portal hypertension increase the risk
of perioperative hemorrhage requiring transfusions, impair liver
regeneration and increase the risk of liver failure. Even in relatively
current series, operative mortality of 8% for extended hepatec-
tomy in patients with HCC has been reported.18 Importantly,
however, overall morbidity and mortality after resection for HCC
have significantly decreased, with most major centers now report-
ing mortality rates <5% with lower operative blood loss and trans-
fusion rates.19,20,21
Post-operative morbidity has been significantly associated
with degree of underlying liver dysfunction, small liver remnant
volume, blood loss, transfusion, and co-morbidities. The most
effective strategies to minimize post-operative morbidity after
resection relate to careful patient selection particularly in patients
with cirrhosis based on assessment of liver function and restric-
tion of resection to patients with compensated Childs A cirrhosis
without portal hypertension, the use of parenchymal sparing
resections, and the use of intraoperative techniques to minimize
blood loss, such as low central venous pressure anesthetic man-
agement and intermittent portal triad clamping.22
The overall 5-year survival of 25–50% after hepatic resection
for patients with HCC supports its therapeutic role. Importantly,
however, resection does not address the remnant liver. Conse-
quently, long-term outcome for patients with cirrhosis is poor
because of the progressive decompensation of the cirrhotic liver
with liver failure and ongoing hepatocarcinogenesis. Survival after
resection has been associated with many clinical and pathologic
factors. Tumor factors associated with reduced survival include
high serum alpha-fetoprotein levels (>1000), size and number of
HCC, and vascular invasion. The risk of microscopic vascular
invasion increases proportionally to HCC size. Overall 5-year
survival rates >50% have been reported for patients with small,
solitary HCC and preserved liver function.20,23,24
The type and extent of resection have been associated with
outcome based on reports of clinical series. Anatomic hepatec-
tomy which is defined as an uni- or multisegmental resection that
includes the portal venous branches to the segment(s) harboring
the HCC has been associated with improved survival24 but is
unsupported by prospective study and other retrospective clinical
series. Although wide margins (1–2 cm) of resection for HCC
have been generally recommended, many retrospective series have
reported similar overall survival and patterns of recurrence for
close margins of resection.25 A recent prospective randomized trial
compared the outcomes of 1 cm versus wide 2 cm margins of
resection in 169 patients with limited HCC. Survival was signifi-
cantly improved for patients with wide margins which provides
strong evidence supporting the importance of surgical margin
status as an outcome predictor after resection of small HCC.26
Multi-focal HCC and major vascular invasion have been associ-
ated with poor survival and have been considered major contrain-
dications to resection. Nonetheless, prolonged overall survival has
been reported in highly selected patients. These factors, however,
are generally associated with >95% recurrence rates and 5-year
overall survival rates of <25%.20,27,28 Resection for single large
HCC (>10 cm) has been associated with favorable long-term sur-
vival and suggests that size alone is not a contraindication for
resection.29,30
Patients with compensated cirrhosis and preserved liver func-
tion who harbor HCC within the Milan criteria (1 HCC < 5 cm or
3 HCC  3 cm) are candidates for either resection or OLT, and
which should be the treatment of choice remains controversial.
Importantly, most reported resection series include many patients
with disease that is well beyond the Milan criteria and therefore
not amenable to OLT, making direct comparison of outcomes
impossible. When analyses are restricted to patients with similar
disease extent, however, the overall survival difference between
resection and OLT narrows. Indeed, overall survival at 5 years
for patients with Milan criteria HCC after resection has been
reportedly similar to that of OLT when accounting for dropouts
while awaiting OLT and prolonged duration of time on wait list,
However, HCC recurrence is greater after resection.
Resection in selected patients with cirrhosis continues to be
recommended because of its broader applicability and reported
survival (35–50% at 5 years). However, accurate identification of
such potential long-term disease-free survivors for resection with
Milan criteria HCC based on current clinicopathological risk
factors remains limited. OLT may be avoided in some patients
because resection has been associated with prolonged recurrence-
free survival. , Although OLT is associated with greater disease-
free survival, nearly 10% of patients recur systemically after OLT,
which similarly indicates refinement of selection criteria for OLT
are needed. Although salvage OLT has been proven safe and effec-
tive in selected patients,31–33 wide application of this approach as
support for standard resection remains highly controversial.
Laparoscopic liver resection
Recently laparoscopic resection for HCC has been reported in
limited clinical series. The majority of laparoscopic resections
have been performed for single, small tumors in accessible parts of
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the liver in highly selected patients. Nonetheless, the reported
series suggest feasibility and no obvious compromise in oncologic
surgical principles.34,35
Consensus statement
1. Resection with wide margins is the treatment of choice for
HCC in patients without cirrhosis and applicable for selected
patients with cirrhosis (Childs-Turcotte-Pugh A without portal
hypertension) with single HCC, regardless of size.
2. Minimizing blood loss and the amount of non-tumoral liver
resected optimizes perioperative outcome.
3. Highly selected patients with multifocal HCC or major vascu-
lar invasion may be candidates for resection but the efficacy of
resection in these patients remains controversial and requires
further clarification.
4. Laparoscopic resection is feasible but unproven.
Liver transplantation for Milan and extended
criteria for HCC
OLT is recognized as the optimal treatment for selected patients
with cirrhosis and HCC, because recurrence and de novo HCC in
the remnant liver are eliminated and hepatic replacement reestab-
lishes normal hepatic synthetic function. Currently only patients
with cirrhosis and early stage HCC are recognized as standard
candidates for OLT36 according to the criteria from the United
Network for Organ Sharing (UNOS). Candidacy for OLT in
patients with cirrhosis and HCC is currently based on estimates
of HCC stage by cross-sectional imaging, usually magnetic
resonance (MR) or computed tomography (CT). Although other
prognostic criteria for HCC such as the presence of microvascular
invasion or genotyping have been proposed for selection of
patients for OLT37,38 the availability and accuracy of such data has
not been widely confirmed regardless of preoperative biopsy.
Thus, most patients with chronic liver disease are considered can-
didates for OLT and undergo evaluation for OLT listing if imaging
depicts a contrast enhanced mass consistent with HCC with the
support of laboratory and clinical features but without tumor
biopsy. Patients with early stage HCC, that is, meeting Milan cri-
teria (see below), are usually listed based on the UNOS point
system for the stage of the underlying liver disease and the added
exception points for HCC. Patients with more advanced stage of
HCC usually undergo therapeutic attempts at downstaging before
transplant listing, although the benefits of such an approach
remain to be firmly established.
Milan criteria
In their landmark report from 1996, Mazzaferro et al. showed that
survival after OLT in patients with cirrhosis and early-stage HCC
was equivalent to that after OLT in patients with similar causes
and stages of chronic liver disease without malignancy.36 The
‘Milan criteria’ of early stage HCC, that is, a single tumor <5 cm or
1- 3 tumors each <3 cm, were subsequently adopted by UNOS in
2002 as the optimal criteria to guide OLT for HCC.36 Organ allo-
cation is based on the Model for End Stage Liver Disease (MELD),
and currently only patients meeting the American Liver Tumor
Study Group (ALTSG) modified TNM stage II39 routinely receive
allocation priority, now receiving a MELD score of 22. The current
allocation priority usually allows for OLT within 6–12 months in
most regions of the U.S.40 Survival after OLT for patients with the
Milan criteria have been excellent and have led to a significant
increase in the number of OLT performed annually in the U.S.
for HCC from about 8.8% prior to 2002 to approximately 22%
in 2006.41,42 Numerous reports have shown that overall 5-year
and 10-year survival after OLT for patients with cirrhosis and
early stage HCC have ranged from 60 to 80% and 50 to 60%,
respectively.43–45 Importantly, however, disease-specific survival
after OLT for patients with cirrhosis and early stage HCC are
excellent in such patients, since recurrence of HCC is uncommon
after OLT.43,44,46 Despite the limitations of the current level of
evidence for clinical studies, the disease-free survival after OLT
clearly exceeds that for partial hepatic resection , which is only in
the range of 20 to 25% by 10 years, even in patients meeting Milan
criteria at the time of hepatic resection.31,32 Although these data
clearly support the primary role of OLT for patients with cirrhosis
and early stage HCC, the disease incidence, the economic and
psychosocial impact of OLT and the fact that some will have
equivalent outcomes after partial hepatic resection dictate further
evaluation of selection criteria and treatment options.
Extended criteria HCC
OLT for patients with chronic liver disease and HCC beyond early
stage disease remains controversial. In the original Milan multi-
center trial,36 13 of the 48 patients with clinical stage II HCC
actually exceeded stage II HCC pathologically in the liver explant.
Survival for these patients was only 45% at 4 years and was sig-
nificantly less than for those patients with early stage HCC.36 This
adverse outcome likely influenced the decision by UNOS not
to allot routine MELD exception points to patients with HCC
beyond stage II. Patients with cirrhosis and HCC beyond Milan
criteria challenge current management approaches, because
unlike patients with stage II HCC, patients with stage III or greater
HCC do not routinely receive MELD priority points despite
otherwise meeting criteria for OLT and most of these patients are
not candidates for standard liver resection. Moreover even when
resection is performed, both overall and disease-free survival is
limited.31 Transplant centers may selectively petition regional
review boards for MELD exception points in patients with HCC
exceeding the Milan criteria. Although patients with such HCC
can be listed for OLT based on their actual MELD point score,
timely OLT before HCC progression is unlikely without additional
exception points. Alternatively OLT in this clinical setting can be
undertaken by using livers from living donors or from very ‘mar-
ginal’ donors from whom organs would not otherwise be utilized.
Although limited availability of donor organs has prompted
criticism of existing exception points for listing patients with
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HCC for OLT, others believe that the current criteria for granting
of exception points are too restrictive and that redefinition of
selection criteria by expanding the maximum tumor size could
allow OLT in more patients without compromising the results.
Investigators at the University of San Francisco have proposed
expanded size criteria for HCC in transplant candidates, ‘UCSF
criteria’,47,48 which includes a single HCC < 6.5 cm in diameter, or
1- 3 HCC with the largest 4.5 cm in diameter and a total HCC
diameter of <8 cm.48 Overall 1- and 5-year survival rates were 90%
and 75% respectively for patients meeting UCSF criteria and
without pre-transplant treatment to downstage HCC. These find-
ings have been corroborated in a case-controlled series44 which
demonstrated equivalent survival after OLT for patients with cir-
rhosis and stage I, II, and III HCC compared to patients with
similar causes and stages of liver disease without HCC during a
similar time period. Thus, the expansion of UNOS criteria to
include patients with stage III HCC as routine candidates for
transplant listing is supported by the disease-specific survival of
nearly 90% and limited recurrence after long-term follow-up.
Downstaging
Screening of patients with liver disease at risk for HCC should
ideally detect early stage disease, for which patients would be
‘transplant eligible’. Unfortunately, many screening programs
remain inconsistently employed, are limited in efficacy and often
detect advanced stage HCC at the initial presentation of previ-
ously unrecognized liver disease. Consequently, HCC is detected
at an advanced disease stage in many patients with chronic liver
disease. Unless listing criteria for OLT in patients with HCC are
revised, candidacy for OLT in patients with more advanced-stage
HCC can only be achieved by downstaging by the use of a neo-
adjuvant therapy. Downstaging of HCC by neoadjuvant therapy
has not been widely investigated. Transarterial chemoemboliza-
tion (TACE) and radiofrequency ablation (RFA) of HCC have
been effectively used to prevent progression of early stage HCC in
patients awaiting OLT,49,50 however, the efficacy of such therapy
for downstaging advanced HCC to Milan criteria is unclear.
Recently neoadjuvant TACE51 was successfully used to downstage
18 of 76 (23.6 %) otherwise unselected patients with stage III/IV
HCC to Milan criteria and, subsequently permitting OLT in 17 of
these 18 patients. Both disease-specific and overall-survival after
OLT in these highly selected patients were 94% with only 1 HCC
recurrence after a median follow-up of 19.6 months. In that
report,51 the average time from initial TACE to OLT was 5.8
months during which time patients had regular follow-up
imaging to assess disease status. This strategy addresses control of
the primary tumor with a loco-regional strategy and avoids sys-
temic therapy during observation, which potentially would allow
detection of occult metastatic disease, if present, and thereby
avoiding an OLT. Whether confirmation of HCC downstaging by
neoadjuvant therapy to meet Milan criteria is too restrictive is
unknown. The outcome of OLT for patients with stable HCC
beyond the Milan criteria after neoadjuvant therapy is unknown.
The role of hepatic resection as neoadjuvant treatment for HCC
is unknown. Broadly neoadjuvant treatment for HCC implies that
OLT will be undertaken provided that criteria for OLT otherwise
are present and extrahepatic HCC has been excluded by imaging.
In this regard, neoadjuvant hepatic resection has not been evalu-
ated. Patients with cirrhosis and HCC who are candidates for
OLT and undergo hepatic resection are not eligible for exception
points under current UNOS guidelines and consequently OLT is
generally precluded by their underlying MELD score. Hepatic
resection for HCC has been employed in patients with com-
pensated cirrhosis (MELD < 9) and followed by OLT as ‘salvage
therapy’ for patients with intrahepatic recurrence. This approach
has been evaluated in patients with HCC eligible for OLT and
reports have differed with outcomes showing equivalent survival
after salvage OLT for recurrent HCC compared to primary OLT33
and significantly worse survival after salvage OLT compared to
primary OLT.52 Hepatic resection has not been used to downstage
HCC to meet criteria for OLT.
These data support a downstaging strategy of loco-regional
therapy for any patient with HCC confined to the liver, but
beyond Milan criteria, who is otherwise a transplant candidate.
Patients who have confirmed downstaging to Milan criteria for a
minimum of 3–6 months after initial TACE should be granted
equivalent MELD exception points as for patients who initially
present with stage II HCC. Patients undergoing loco-regional
therapy with stable intrahepatic disease and no evidence of extra-
hepatic progression for 3–6 months should be considered for OLT
on a case by case basis.
Consensus statement
1. OLT is established as the preferred approach for patients with
cirrhosis and HCC meeting Milan criteria
2. OLT should be considered on a highly selective basis for
patients beyond Milan criteria without pre-transplant down-
staging (e.g. those meeting UCSF criteria)
3. Pre-transplant therapy (TACE and other) with an interval of
observation (3 – 6 months minimum) to assess the biologic
aggressiveness should be considered for patients beyond Milan
criteria. Patients who downstage to meet Milan criteria with no
evidence of extrahepatic disease on re-staging should be
considered for MELD exception points to allow for OLT
Bridge to transplantation therapy for HCC
Bridge to transplantation therapies are used to prevent HCC
progression while patients await OLT. The specific aims of such
therapies are to 1) avoid HCC progression and drop-out on the
waiting list; 2) increase tumor-free survival after OLT; 3) down-
stage advanced HCC to enable OLT; and 4) avoid or delay the
need of OLT for selected patients that respond favorably to bridge
treatment.
Three strategies have been used as bridge therapy to OLT:
TACE or TAE, ablation therapy with either percutaneous ethanol
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injection (PEI) or RFA, and surgical resection. The efficacy of
these therapies remains controversial. In fact, clinical practices are
highly variable, and some centers prefer no therapy at all. Pub-
lished clinical experiences and trials of the different bridge thera-
pies including those without treatment, were reviewed and the
following standard metrics were assessed: 1) tumor response to
therapy; 2) drop-out on the waiting list; 3) survival after OLT; 4)
avoidance or delay of OLT for patients responding to therapy; and
5) treatment related morbidity and mortality. Reports comparing
differences in bridge therapies were examined to determine rela-
tive efficacy, but such analysis is confounded by reports which
include resection, OLT and non-transplantation candidates and
patients treated by multiple bridge therapies. Finally, no random-
ized controlled trial has been designed to demonstrate efficacy
of any bridge therapy for patients awaiting OLT.
Natural history (no treatment)
The natural history of untreated HCC presenting within trans-
plant criteria is well known.53 At least 70% of patients will have
tumor growth, 20% will develop vascular invasion, and 9% will
develop metastases within one year of diagnosis. The risk of drop-
out (disease progression beyond transplant criteria) is approxi-
mately 20% during the first six months while awaiting OLT.
TACE and TAE
There are no randomized controlled trials demonstrating efficacy
with either a decrease in drop-out on the waiting list or improved
survival after OLT. Efficacy is supported by observations of tumor
response to treatment and comparison of drop-out rates with
historical controls. Several randomized controlled trials have
demonstrated tumor responses and improved survival in nonsur-
gical patients treated with TACE or TAE compared to untreated
controls.54,55 Uncontrolled series have shown low drop-out rates
achieved in patients treated with TACE, 0–15% at 6 months and
0–25% at 12 months.56,57 TACE associated morbidity has been
less than 5%.55,58 Although TACE is more widely used than TAE,
the efficacy and safety of TACE and TAE are similar.59,60 A single
randomized prospective trial has demonstrated greater rates of
HCC response with TACE and thymalfasin.61
RFA and PEI
No randomized controlled trial has demonstrated less drop-out or
increased survival due to RFA or PEI in patients awaiting OLT.
Several studies have demonstrated HCC response to therapy,
less than expected HCC progression, and lower than expected
drop-out rates for patients awaiting OLT.11,62–66
Liver resection
Liver resection as a bridge to OLT is controversial. Although OLT
is clearly feasible after resection, there are conflicting reports
regarding the increased operative risk of OLT in patients previ-
ously submitted to a partial hepatectomy.33,52 Approximately 70%
of patients develop recurrent HCC after resection, but many are
not candidates for OLT.52 Liver decompensation soon after resec-
tion is salvageable by OLT. An advantage of liver resection as
bridge therapy is that accurate pathological staging and identifi-
cation of poor prognostic factors for HCC are available prior to
OLT. Unlike other bridge therapies, resection may avoid or delay
OLT. Selected patients with small HCC and low MELD scores
achieve reasonable survival with resection alone.67,68 Finally, liver
resection as a bridge to OLT is problematic in the United States
because resection precludes MELD score exception points for
patients on the waiting list.
Combined experience and comparative data
Despite demonstrable HCC responses to TACE and RFA, overall
efficacy remains controversial.13,69 Survival after OLT for patients
that have and have not undergone bridge therapy is similar.13
Nevertheless, intention-to-treat analyses suggest that bridge
therapy is effective for patients with anticipated waiting times
longer than 6 months.69
Comparison studies of bridge therapies have been conducted
in both non-surgical patients and those awaiting OLT. These
studies show that small central HCC may be better treated with
RFA than TACE,63 combined TACE and RFA and RFA alone have
equal efficacy for the treatment of small (3 cm) HCC (12);
results with RFA exceed those with PEI;65,66 and results with RFA
are comparable to resection.11,65
Downstaging
Treatment with RFA, TACE, or resection has achieved downstag-
ing of HCC exceeding Milan criteria and enabled 21 of 30 highly
selected patients to undergo OLT.70 Although median follow-up
was only 16 months, no patient developed recurrent HCC. Suc-
cessful downstaging from TACE was achieved in 18 of 76 (24%)
patients with stage III and IV disease.51 Seventeen underwent OLT
and overall and disease-free survival was 96% at a median
follow-up of 19.6 months with only one recurrent HCC. These
findings clearly demonstrate the potential of bridge therapies to
achieve significant tumor responses in patients with HCC beyond
standard transplant criteria. A survival advantage is evident for
these patients because none would have survived without OLT or
otherwise been a candidate for OLT without bridge therapy.
Consensus statement
1. Bridge to transplantation therapy with TACE and RFA have
low morbidity, are associated with favorable HCC responses,
and probably reduce drop-out due to HCC progression for
patients waiting at least 6 months to undergo OLT.
2. Liver resection may be a bridge to OLT or delay and possibly
avoid the need of OLT for highly selected patients with small
tumors and low MELD scores.
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